1.Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting.
Feng Roger LUO ; Jian DING ; Helen X CHEN ; Hao LIU ; Man-Cheong FUNG ; Maria KOEHLER ; Jean Pierre ARMAND ; Lei JIANG ; Xiao XU ; Ge ZHANG ; Li XU ; Pascal QIAN ; Li YAN
Chinese Journal of Cancer 2014;33(12):620-624
The US Chinese Anti-Cancer Association (USCACA) teamed up with Chinese Society of Clinical Oncology (CSCO) to host a joint session at the17th CSCO Annual Meeting on September 20th, 2014 in Xiamen, China. With a focus on breakthrough cancer medicines, the session featured innovative approaches to evaluate breakthrough agents and established a platform to interactively share successful experiences from case studies of 6 novel agents from both the United States and China. The goal of the session is to inspire scientific and practical considerations for clinical trial design and strategy to expedite cancer drug development in China. A panel discussion further provided in-depth advice on advancing both early and full development of novel cancer medicines in China.
Antineoplastic Agents
;
China
;
Drug Discovery
;
Humans
;
Medical Oncology
;
Neoplasms
;
Societies, Medical
;
United States
Result Analysis
Print
Save
E-mail